NuVasive, Inc. (NASDAQ:NUVA) CEO Gregory T. Lucier bought 2,000 shares of NuVasive stock in a transaction dated Tuesday, August 29th. The stock was acquired at an average price of $61.52 per share, with a total value of $123,040.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Shares of NuVasive, Inc. (NASDAQ NUVA) opened at 62.48 on Friday. The firm has a market capitalization of $3.17 billion, a PE ratio of 98.39 and a beta of 1.06. NuVasive, Inc. has a 12 month low of $56.70 and a 12 month high of $81.68. The firm’s 50 day moving average is $68.96 and its 200-day moving average is $73.32.

NuVasive (NASDAQ:NUVA) last posted its earnings results on Thursday, July 27th. The medical device company reported $0.46 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.02. The firm had revenue of $260.60 million during the quarter, compared to the consensus estimate of $261.95 million. NuVasive had a net margin of 3.50% and a return on equity of 13.04%. The company’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.40 EPS. On average, analysts expect that NuVasive, Inc. will post $2.00 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/01/insider-buying-nuvasive-inc-nuva-ceo-purchases-123040-00-in-stock.html.

A number of equities research analysts have recently commented on NUVA shares. BidaskClub upgraded shares of NuVasive from a “hold” rating to a “buy” rating in a research report on Wednesday, July 19th. Zacks Investment Research cut shares of NuVasive from a “hold” rating to a “sell” rating in a research report on Tuesday, June 27th. Royal Bank Of Canada increased their target price on shares of NuVasive from $76.00 to $85.00 and gave the company an “outperform” rating in a research report on Tuesday, June 6th. Morgan Stanley reiterated an “equal weight” rating and issued a $88.00 target price (up from $84.00) on shares of NuVasive in a research report on Tuesday, July 25th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $90.00 target price (up from $85.00) on shares of NuVasive in a research report on Wednesday, June 28th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $81.18.

A number of hedge funds have recently bought and sold shares of NUVA. Vanguard Group Inc. increased its stake in NuVasive by 1.3% in the second quarter. Vanguard Group Inc. now owns 4,164,226 shares of the medical device company’s stock worth $320,312,000 after buying an additional 53,769 shares during the period. Champlain Investment Partners LLC increased its stake in NuVasive by 2.3% in the first quarter. Champlain Investment Partners LLC now owns 1,908,280 shares of the medical device company’s stock worth $142,510,000 after buying an additional 42,395 shares during the period. State Street Corp increased its stake in NuVasive by 4.2% in the second quarter. State Street Corp now owns 1,710,341 shares of the medical device company’s stock worth $131,562,000 after buying an additional 68,344 shares during the period. Voya Investment Management LLC increased its stake in NuVasive by 43.7% in the second quarter. Voya Investment Management LLC now owns 1,699,964 shares of the medical device company’s stock worth $130,761,000 after buying an additional 517,115 shares during the period. Finally, Eagle Asset Management Inc. increased its stake in NuVasive by 10.4% in the first quarter. Eagle Asset Management Inc. now owns 1,428,644 shares of the medical device company’s stock worth $106,691,000 after buying an additional 134,729 shares during the period.

About NuVasive

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Insider Buying and Selling by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Stock Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related stocks with our FREE daily email newsletter.